A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

ABSTRACT Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v.

3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective responses were seen in 14/24 (58%) patients with regimen A (4 complete) and

6/24 (25%) with regimen B (1 complete) (P less than 0.02). The median duration of response was 14 months with regimen A and 6.5 months with regimen B. The median duration of survival was 20

months and 8 months respectively (P less than 0.01). The toxicity was similar with each regimen. There was no evidence of deterioration in left ventricular ejection fraction nor congestive

heart failure in any patient. It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage.

Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this

journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now

Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support SIMILAR CONTENT BEING VIEWED BY OTHERS DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY IN THE TRASTUZUMAB ERA: FINAL LONG-TERM RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE

III HE10/05 TRIAL Article 24 May 2022 A CAREFUL REASSESSMENT OF ANTHRACYCLINE USE IN CURABLE BREAST CANCER Article Open access 08 October 2021 THE IMPACT OF ANTHRACYCLINES IN INTERMEDIATE

AND HIGH-RISK HER2-NEGATIVE EARLY BREAST CANCER—A POOLED ANALYSIS OF THE RANDOMISED CLINICAL TRIALS PLANB AND SUCCESS C Article Open access 22 February 2022 AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Instituto Portugues de Oncologia Francisco Gentil, Lisboa, Portugal J Carmo-Pereira Authors * J Carmo-Pereira View author publications You can also search for this author

inPubMed Google Scholar * FO Costa View author publications You can also search for this author inPubMed Google Scholar * Elivra Henriques View author publications You can also search for

this author inPubMed Google Scholar * F Godinho View author publications You can also search for this author inPubMed Google Scholar * MG Cantinho-Lopes View author publications You can also

search for this author inPubMed Google Scholar * A Sales-Luis View author publications You can also search for this author inPubMed Google Scholar * RD Rubens View author publications You

can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Carmo-Pereira, J., Costa, F., Henriques, E. _et

al._ A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. _Br J Cancer_ 56, 471–473 (1987). https://doi.org/10.1038/bjc.1987.226 Download

citation * Issue Date: 01 December 1987 * DOI: https://doi.org/10.1038/bjc.1987.226 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative